Positron emission tomography combined with computed tomography using carbon-11 acetate (ACT PET/CT) may help detect lesions before treatment and evaluate response following therapy in patients with from multiple myeloma (MM). This study aimed to prospectively assess the clinical utility of ACT PET/CT in MM as compared to the commonly used F18-fluorodeoxyglucose(FDG).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
30
Old tracer but new indication
Chang Gung Memorial Hostpial
Guishan, Taoyuan county, Taiwan
Pretreatment lesion detection
Reference standards: bone marrow examination and whole-body dynamic contrast-enhanced MRI
Time frame: Within 2 weeks before initiation of therapy
Post-induction response assessment
Reference standard: clinical response based on International Uniform Criteria and bone marrow examination if any
Time frame: Approximately 4 months after initiation of therapy depending on the regimen
Post-ASCT response assessment
Reference standard: clinical response based on International Uniform Criteria and bone marrow examination if any
Time frame: Approximately 3 months after ASCT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.